Maintained strong balance sheet with $329M including funds as of August 31, 2023 and $60 million upfront received from Seagen in the fourth quarter of 2023. Based on our current operating plan Nurix has cash runway into the second half of 2025.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on NRIX:
- Nurix Therapeutics to Present at 42nd Annual J.P. Morgan Healthcare Conference
- Nurix Therapeutics to hold a pharmaceutical update conference call
- Oppenheimer says too early to make call on Nurix Therapeutics’ NX-5948
- Nurix Therapeutics Presents Positive Clinical Data from Its Novel Bruton’s Tyrosine Kinase (BTK) Degrader Programs, NX-5948 and NX-2127, at the 65th American Society of Hematology (ASH) Annual Meeting
- Nurix Therapeutics presents clinical data from NX-5948, NX-2127 programs
